Rucaparib 'Very Active' for High-Grade Ovarian Cancer

Dr Maurie Markman reports on high response rates to rucaparib therapy for ovarian cancer and looks forward to future research efforts using this PARP inhibitor.

Source: Medscape Oncology - March 22, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts